A Day Up For Vaccinex, Inc.
Vaccinex, Inc. (VCNX:NASDAQ) soared at $3, a gain of 30.4%. The stock appeared on our News Catalysts scanner on Wed, May 19, 2021 at 08:25 AM in the 'BIOTECH' category. From Fri, May 21, 2021, the stock recorded 44.44% Up Days and 50.00% Green Days
The stock spiked on Fri, Mar 12, 2021 at $4.16 with a volume of 3M+, and its share price has been moving sideways in recent weeks.
About Vaccinex, Inc. (VCNX:NASDAQ)
Vaccinex Inc is a clinical-stage biotechnology company. It is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. Its lead product candidate VX15 is in clinical development for the treatment of NSCLC, osteosarcoma and Huntington's disease and additional product candidates VX5 and VX25 are in earlier stages of development.
Top 10 Gainers:
- Ra Medical Systems, Inc. (RMED:NYSE), 87.3%
- EXFO Inc. (EXFO:NASDAQ), 60.27%
- NextDecade Corporation (NEXT:NASDAQ), 42.62%
- Biogen Inc. (BIIB:NASDAQ), 38.34%
- Urban One, Inc. (UONE:NASDAQ), 35.6%
- CLOV (CLOV:NASDAQ), 32.44%
- Vaccinex, Inc. (VCNX:NASDAQ), 30.43%
- Atossa Therapeutics, Inc. (ATOS:NASDAQ), 30.09%
- Prothena Corporation plc (PRTA:NASDAQ), 29.95%
- U.S. Concrete, Inc. (USCR:NASDAQ), 29.28%